Describing Written Description: The Implications of Ariad

China IP Magazine
June 2010

This article outlines and analyzes the issues and implications in Ariad Pharmaceuticals, Inc. et al. v. Eli Lilly Company, 2008-1248 (Fed. Cir. March 22, 2010) regarding the written description requirement under 35 U.S.C. § 112 and provides practical tips for the patent practitioner in light of the Ariad decision.

View Attachment (PDF)